JP2020506895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506895A5 JP2020506895A5 JP2019538180A JP2019538180A JP2020506895A5 JP 2020506895 A5 JP2020506895 A5 JP 2020506895A5 JP 2019538180 A JP2019538180 A JP 2019538180A JP 2019538180 A JP2019538180 A JP 2019538180A JP 2020506895 A5 JP2020506895 A5 JP 2020506895A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- membered
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000005842 heteroatom Chemical group 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 25
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 229910052717 sulfur Inorganic materials 0.000 claims 23
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 4
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims 3
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 3
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 3
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 0 C*C(*)([C@@]1C2*)[C@@]1C(*)C2*(*)=S Chemical compound C*C(*)([C@@]1C2*)[C@@]1C(*)C2*(*)=S 0.000 description 7
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 2
- NDLWRNDHOJPLTE-UHFFFAOYSA-N CC(C)Oc1ncc(C)cn1 Chemical compound CC(C)Oc1ncc(C)cn1 NDLWRNDHOJPLTE-UHFFFAOYSA-N 0.000 description 1
- QYOFIWQGXQGNMB-UHFFFAOYSA-N CCCOc1ncc(C)cn1 Chemical compound CCCOc1ncc(C)cn1 QYOFIWQGXQGNMB-UHFFFAOYSA-N 0.000 description 1
- NDLQVGMDCZDJQP-ORQPDHAQSA-O CCOC(/C=C\C(C)=N)=[NH2+] Chemical compound CCOC(/C=C\C(C)=N)=[NH2+] NDLQVGMDCZDJQP-ORQPDHAQSA-O 0.000 description 1
- KUQQONVKIURIQU-UHFFFAOYSA-N Cc(c(F)c1)ccc1C#N Chemical compound Cc(c(F)c1)ccc1C#N KUQQONVKIURIQU-UHFFFAOYSA-N 0.000 description 1
- MKFCYQTVSDCXAQ-UHFFFAOYSA-N Cc(c(F)c1)ccc1Cl Chemical compound Cc(c(F)c1)ccc1Cl MKFCYQTVSDCXAQ-UHFFFAOYSA-N 0.000 description 1
- MPXDAIBTYWGBSL-UHFFFAOYSA-N Cc(c(F)c1)ccc1F Chemical compound Cc(c(F)c1)ccc1F MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 1
- WQOHEWKWIJOAHQ-UHFFFAOYSA-N Cc(c(F)c1)ccc1OC Chemical compound Cc(c(F)c1)ccc1OC WQOHEWKWIJOAHQ-UHFFFAOYSA-N 0.000 description 1
- YSNVKDGEALPJGC-UHFFFAOYSA-N Cc(cc(cc1)F)c1F Chemical compound Cc(cc(cc1)F)c1F YSNVKDGEALPJGC-UHFFFAOYSA-N 0.000 description 1
- XPUXIETZGSTMEX-UHFFFAOYSA-N Cc(cc1)cc(OCC(F)F)c1Cl Chemical compound Cc(cc1)cc(OCC(F)F)c1Cl XPUXIETZGSTMEX-UHFFFAOYSA-N 0.000 description 1
- JUXFXYQUXNXVAA-UHFFFAOYSA-N Cc(cc1)ccc1OC(F)(F)F Chemical compound Cc(cc1)ccc1OC(F)(F)F JUXFXYQUXNXVAA-UHFFFAOYSA-N 0.000 description 1
- DJDQNISEJVPQCS-UHFFFAOYSA-N Cc(cc1)ccc1OC(F)F Chemical compound Cc(cc1)ccc1OC(F)F DJDQNISEJVPQCS-UHFFFAOYSA-N 0.000 description 1
- NFQGQMBFMIIIOR-UHFFFAOYSA-N Cc(cc1)cnc1OC Chemical compound Cc(cc1)cnc1OC NFQGQMBFMIIIOR-UHFFFAOYSA-N 0.000 description 1
- WCGNLBCJPBKXCN-UHFFFAOYSA-N Cc(cc1F)ccc1C#N Chemical compound Cc(cc1F)ccc1C#N WCGNLBCJPBKXCN-UHFFFAOYSA-N 0.000 description 1
- MHXNHUSVBYUTJL-UHFFFAOYSA-N Cc(cc1F)ccc1Cl Chemical compound Cc(cc1F)ccc1Cl MHXNHUSVBYUTJL-UHFFFAOYSA-N 0.000 description 1
- FZMPLKVGINKUJZ-UHFFFAOYSA-N Cc(cc1F)ccc1F Chemical compound Cc(cc1F)ccc1F FZMPLKVGINKUJZ-UHFFFAOYSA-N 0.000 description 1
- MSQWWFRWHKYEAU-UHFFFAOYSA-N Cc(cc1OC(F)F)ccc1Cl Chemical compound Cc(cc1OC(F)F)ccc1Cl MSQWWFRWHKYEAU-UHFFFAOYSA-N 0.000 description 1
- KBRLTYHUJDMMLI-UHFFFAOYSA-N Cc(cc1OC)ccc1Cl Chemical compound Cc(cc1OC)ccc1Cl KBRLTYHUJDMMLI-UHFFFAOYSA-N 0.000 description 1
- LPVVVCBDJJRLHT-UHFFFAOYSA-N Cc(nc1)ccc1OC Chemical compound Cc(nc1)ccc1OC LPVVVCBDJJRLHT-UHFFFAOYSA-N 0.000 description 1
- LRLRAYMYEXQKID-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cc1 Chemical compound Cc1ccc(C(F)(F)F)cc1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 1
- CSDACMXHCXPONB-UHFFFAOYSA-N Cc1ccc(C)c(OCC(F)(F)F)c1 Chemical compound Cc1ccc(C)c(OCC(F)(F)F)c1 CSDACMXHCXPONB-UHFFFAOYSA-N 0.000 description 1
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N Cc1n[o]c(C)c1 Chemical compound Cc1n[o]c(C)c1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- XHANCLXYCNTZMM-UHFFFAOYSA-N Cc1nc2cc(C)ccc2[s]1 Chemical compound Cc1nc2cc(C)ccc2[s]1 XHANCLXYCNTZMM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447368P | 2017-01-17 | 2017-01-17 | |
| US62/447,368 | 2017-01-17 | ||
| US201762458777P | 2017-02-14 | 2017-02-14 | |
| US62/458,777 | 2017-02-14 | ||
| US201762528366P | 2017-07-03 | 2017-07-03 | |
| US62/528,366 | 2017-07-03 | ||
| PCT/US2018/013914 WO2018136437A2 (en) | 2017-01-17 | 2018-01-16 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506895A JP2020506895A (ja) | 2020-03-05 |
| JP2020506895A5 true JP2020506895A5 (OSRAM) | 2021-02-25 |
Family
ID=62908947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538180A Pending JP2020506895A (ja) | 2017-01-17 | 2018-01-16 | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11173145B2 (OSRAM) |
| EP (1) | EP3570832A4 (OSRAM) |
| JP (1) | JP2020506895A (OSRAM) |
| CN (1) | CN110191709A (OSRAM) |
| CA (1) | CA3047002A1 (OSRAM) |
| WO (1) | WO2018136437A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110191709A (zh) | 2017-01-17 | 2019-08-30 | 德州大学系统董事会 | 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物 |
| WO2020018670A1 (en) * | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| KR102833434B1 (ko) * | 2018-09-27 | 2025-07-15 | 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. | 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체 |
| WO2020092183A1 (en) | 2018-11-01 | 2020-05-07 | Merck Sharp & Dohme Corp. | Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| WO2020112581A1 (en) * | 2018-11-28 | 2020-06-04 | Merck Sharp & Dohme Corp. | Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors |
| MX2021014441A (es) * | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| CN112107685A (zh) * | 2020-07-17 | 2020-12-22 | 深圳市第二人民医院 | 一种基于ido1酶抑制剂设计的治疗骨关节炎的方法 |
| CN115215780B (zh) * | 2022-04-22 | 2023-08-08 | 上海格苓凯生物科技有限公司 | 一种利用n,n-二琥珀酰亚胺基碳酸酯制备异双功能交联剂smcc的方法 |
| EP4535004A4 (en) * | 2022-05-27 | 2025-09-17 | Fujifilm Corp | METHOD FOR AID IN THE DIAGNOSIS OF A BLOOD TUMOR, METHOD FOR OBTAINING DATA FOR THE DIAGNOSIS OF A BLOOD TUMOR AND KIT FOR SAID METHODS |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177280A (en) | 1978-07-03 | 1979-12-04 | Syntex (U.S.A.) Inc. | Bicyclo[3.1.0]hexyl-substituted carbonylaminophenoxy cardiovascular agents |
| US5705511A (en) | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| GB9821199D0 (en) | 1998-09-30 | 1998-11-25 | Glaxo Group Ltd | Chemical compounds |
| EP1546099B1 (en) * | 2002-07-08 | 2008-12-31 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists |
| US20040077617A1 (en) | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Fused cycloalkyl amides and acids and their therapeutic applications |
| HRP20100619T1 (hr) | 2003-06-26 | 2011-01-31 | Taisho Pharmaceutical Co. | Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera |
| GB0322016D0 (en) | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| ES2652440T3 (es) * | 2004-04-02 | 2018-02-02 | OSI Pharmaceuticals, LLC | Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico |
| WO2006005185A1 (en) | 2004-07-13 | 2006-01-19 | The University Of British Columbia | Indoleamine 2,3-dioxygenase (ido) inhibitors |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| BR122020016659B8 (pt) | 2005-05-10 | 2021-07-27 | Incyte Holdings Corp | moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| JP2011518841A (ja) | 2008-04-24 | 2011-06-30 | ニューリンク ジェネティクス， インコーポレイテッド | Ｉｄｏ阻害剤 |
| RS57132B1 (sr) | 2008-07-08 | 2018-07-31 | Incyte Holdings Corp | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze |
| WO2010122968A1 (ja) | 2009-04-21 | 2010-10-28 | アステラス製薬株式会社 | ジアシルエチレンジアミン化合物 |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| CN103339115B (zh) | 2010-11-13 | 2016-08-31 | 茵库恩制药有限公司 | 金属酶抑制剂化合物 |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| NO2694640T3 (OSRAM) | 2011-04-15 | 2018-03-17 | ||
| WO2013062680A1 (en) | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| ES2651484T3 (es) | 2011-11-09 | 2018-01-26 | Kyowa Hakko Kirin Co., Ltd. | Compuesto heterocíclico que contiene nitrógeno |
| CN102532144B (zh) | 2012-01-20 | 2014-09-10 | 辽宁思百得医药科技有限公司 | 一种新型吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途 |
| US9309243B2 (en) | 2012-07-13 | 2016-04-12 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| PE20151593A1 (es) | 2013-03-14 | 2015-11-05 | Newlink Genetics Corp | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano |
| TR201810399T4 (tr) | 2013-03-15 | 2018-08-27 | Gilead Sciences Llc | İndolamin 2,3-dioksijenaz (ıdo) inhibitörleri. |
| KR20150129010A (ko) | 2013-03-15 | 2015-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | Ido 억제제 |
| EA029126B1 (ru) | 2013-07-01 | 2018-02-28 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| CN103570726B (zh) | 2013-07-15 | 2016-04-06 | 上海天慈生物谷生物工程有限公司 | N-烷基色胺酮衍生物及其制备方法和应用 |
| CN105658643B (zh) | 2013-08-27 | 2019-03-01 | 百时美施贵宝公司 | Ido抑制剂 |
| CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
| WO2015082499A2 (en) | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| KR20160108568A (ko) | 2014-02-04 | 2016-09-19 | 인사이트 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합 |
| WO2015150097A1 (en) | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| CN106536480B (zh) | 2014-05-15 | 2019-09-03 | 艾特奥斯治疗公司 | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 |
| RU2016149812A (ru) | 2014-06-06 | 2018-07-17 | Флексус Байосайенсиз, Инк. | Иммунорегулирующие средства |
| AU2015302908B2 (en) | 2014-08-13 | 2020-02-13 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy |
| GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| TW201619133A (zh) | 2014-08-21 | 2016-06-01 | 裘拉德製藥私人有限公司 | 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物 |
| ES2751602T3 (es) | 2014-09-05 | 2020-04-01 | Merck Patent Gmbh | Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer |
| CN105481789B (zh) | 2014-09-15 | 2020-05-19 | 中国科学院上海有机化学研究所 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 |
| GB201417369D0 (en) | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| GB201418300D0 (en) | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| CA2965741C (en) | 2014-11-03 | 2022-05-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| MX2017005462A (es) * | 2014-11-05 | 2017-07-28 | Flexus Biosciences Inc | Agentes inmunorreguladores. |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| AR104176A1 (es) | 2015-04-03 | 2017-07-05 | Bristol Myers Squibb Co | Inhibidores de ido (indolamina-2,3-dioxigenasa) |
| WO2016161960A1 (en) * | 2015-04-10 | 2016-10-13 | Beigene, Ltd. | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
| AU2016284812A1 (en) | 2015-06-26 | 2018-02-15 | Bristol-Myers Squibb Company | IDO inhibitors |
| RU2018112830A (ru) | 2015-09-24 | 2019-10-24 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Модуляторы индоламин-2,3-диоксигеназы |
| EP3353167B1 (en) | 2015-09-24 | 2020-06-24 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Modulators of indoleamine 2,3-dioxygenase |
| AU2017217536A1 (en) | 2016-02-09 | 2018-08-09 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
| CN109348714A (zh) | 2016-05-04 | 2019-02-15 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| JP2019516682A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| KR20190004743A (ko) | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| EP3503891A1 (en) | 2016-08-26 | 2019-07-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN110191709A (zh) | 2017-01-17 | 2019-08-30 | 德州大学系统董事会 | 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物 |
| WO2018136887A1 (en) | 2017-01-23 | 2018-07-26 | Tesaro, Inc. | Compounds |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
-
2018
- 2018-01-16 CN CN201880006825.0A patent/CN110191709A/zh active Pending
- 2018-01-16 US US16/478,076 patent/US11173145B2/en active Active
- 2018-01-16 JP JP2019538180A patent/JP2020506895A/ja active Pending
- 2018-01-16 EP EP18741114.5A patent/EP3570832A4/en not_active Withdrawn
- 2018-01-16 CA CA3047002A patent/CA3047002A1/en not_active Abandoned
- 2018-01-16 WO PCT/US2018/013914 patent/WO2018136437A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506895A5 (OSRAM) | ||
| JP2019516766A5 (OSRAM) | ||
| JP2017535589A (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP2015532295A5 (OSRAM) | ||
| JP2019529500A5 (OSRAM) | ||
| JP2019535746A5 (OSRAM) | ||
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2015517574A5 (OSRAM) | ||
| JP2014507421A5 (OSRAM) | ||
| JP2014518544A5 (OSRAM) | ||
| JP2014503567A5 (OSRAM) | ||
| JP2015524457A5 (OSRAM) | ||
| CN112469718A (zh) | 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用 | |
| JP2017528498A5 (OSRAM) | ||
| JP2019518766A5 (OSRAM) | ||
| JP2011511095A5 (OSRAM) | ||
| JP2013509431A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2012506381A5 (OSRAM) | ||
| JP2017522377A (ja) | 白金化合物、組成物、及びそれらの使用 | |
| JP2020527173A5 (OSRAM) | ||
| JP2017519754A5 (OSRAM) | ||
| JP2011509309A5 (OSRAM) | ||
| JP2020536971A5 (OSRAM) | ||
| RU2013112871A (ru) | Соединения для лечения рака |